SEARCH:   Advanced

Blood, 1 February 2005, Vol. 105, No. 3, pp. 1348-1354. Prepublished online as a Blood First Edition Paper on September 28, 2004; DOI 10.1182/blood-2004-07-2528. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-07-2528v1 105/3/1348    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sanders, J. E. Articles by Appelbaum, F. R. Search for Related Content PubMed PubMed Citation Articles by Sanders, J. E. Articles by Appelbaum, F. R. Related Collections Transplantation Clinical Trials and Observations Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Final adult height of patients who received hematopoietic cell transplantation in childhood Jean E. Sanders, Katherine A. Guthrie, Paul A. Hoffmeister, Ann E. Woolfrey, Paul A. Carpenter, and Frederick R. Appelbaum From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle; the Departments of Pediatrics and Medicine, University of Washington School of Medicine, Seattle; and the Department of Biostatistics, University of Washington School of Public Health and Community Medicine, Seattle. Growth impairment and growth hormone (GH) deficiency are complications after total body irradiation (TBI) and hematopoietic cell transplantation (HCT). To determine the impact of GH therapy on growth, the final heights of 90 GH-deficient children who underwent fractionated TBI and HCT for malignancy were evaluated. Changes in height standard deviation (SD) from the diagnosis of GH deficiency to the achievement of final height were compared among 42 who did and 48 who did not receive GH therapy. At HCT, GH-treated patients were younger (P = .001), more likely to have undergone central nervous system irradiation (P = .007), and shorter (P = .005) than patients who did not receive GH therapy. After HCT, GH deficiency was diagnosed at 1.5 years (range, 0.8-9.5 years) for GH-treated and 1.2 years (range, 0.9-8.8 years) for nontreated patients. GH therapy was associated with significantly improved final height in children younger than 10 years at HCT (P = .0001), but GH therapy did not impact the growth of older children. Girls (P = .0001) and children diagnosed with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), or myelodysplastic syndromes (MDS) (compared with acute lymphoblastic leukemia [ALL] or non-Hodgkin lymphoma [NHL]; P = .02) also showed more rapid growth than their counterparts. These data demonstrate that GH therapy improves the final height of young children after fractionated TBI. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Final height after transplantation in childhood Boudewijn Bakker, Wilma Oostdijk, Jan M. Wit, and Jean E. Sanders Blood 2005 106: 2592-2593. [Full Text] [PDF] This article has been cited by other articles: E. A. Copelan Hematopoietic stem-cell transplantation. N. Engl. J. Med., April 27, 2006; 354(17): 1813 - 1826. [Full Text] [PDF] B. Bakker, W. Oostdijk, J. M. Wit, and J. E. Sanders Final height after transplantation in childhood Blood, October 1, 2005; 106(7): 2592 - 2593. [Full Text] [PDF] Minerva BMJ, February 5, 2005; 330(7486): 316 - 316. [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020